Pure Global AI
NCT06154668Not yet recruiting

Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma Patients

Phenotypic, Functional, Metabolic and Transcriptomic Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma Patients
University Hospital, GrenobleClinicalTrials.gov
Verified
Study focus
Disease/Condition
Melanoma
Study type
Observational
Sponsor & location
Primary sponsor
University Hospital, Grenoble
Timeline & enrollment
Phase
N/A
Start date
Dec 01, 2023
End date
Dec 01, 2031
Enrollment
707 participants
Primary outcome

Identification of biomarkers of response to anti6PD1 according to the type of patient before the start of treatment

Summary

Despite being standard of care, there are still many medical requirements related to immune
 checkpoint blocker based therapies such as identify patients susceptible to respond with the
 less adverse events, evaluate the clinical benefit of adjuvant treatment /risk of relapse and
 design new strategies for non-responder patients.
 
 Thus, this project aims at understanding the impact of anti-PD1 on the immune system through
 investigation of the phenotypic, functional, metabolic and transcriptomic profiles of
 circulating DC subsets and effectors in response to anti-PD1 therapy in melanoma patients.
 
 The primary objective of the study is to identify the biomarkers of response to anti-PD1
 according to the type of patient before the start of the treatment.

ICD-10 classifications
Malignant melanoma of skinMelanoma in situ, unspecifiedMelanoma in situMelanoma and other malignant neoplasms of skinMalignant neoplasm: Malignant melanoma of skin, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06154668
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06154668 through Pure Global AI's free database. This phase not specified trial is sponsored by University Hospital, Grenoble and is currently Not yet recruiting. The study focuses on Melanoma. Target enrollment is 707 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.